Ascendiant analyst Edward Woo maintained a Buy rating on SurgePays (SURG – Research Report) on April 2 and set a price target of $9.50. The company’s shares closed yesterday at $5.05.
Woo covers the Healthcare sector, focusing on stocks such as Vivos Therapeutics, Biolase, and Plus Therapeutics. According to TipRanks, Woo has an average return of -1.6% and a 41.03% success rate on recommended stocks.
Currently, the analyst consensus on SurgePays is a Moderate Buy with an average price target of $12.25, which is a 142.57% upside from current levels. In a report released on March 31, Maxim Group also reiterated a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on SurgePays’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $36.17 million and a GAAP net loss of $1.54 million. In comparison, last year the company earned a revenue of $14.16 million and had a GAAP net loss of $6.84 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Surgepays Inc is a fintech company. It provides services to financial technology, telecommunications, and digital media companies. The company offers prepaid wireless and underbanked financial products and services, along with popular consumer goods, to retail merchants such as operators of convenience stores, bodegas, and gas stations. Its operating segment includes Surge Blockchain and Other; Surge Logics; TW and ECS (Electronic Check Services).
Read More on SURG:
